PubRank

Thomas C Chen

Author PubWeight™ 58.45‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007 2.82
2 Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009 2.61
3 Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 2005 1.68
4 Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004 1.65
5 Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008 1.58
6 Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 2007 1.41
7 Primary intraosseous meningioma. Neurosurg Focus 2007 1.39
8 HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007 1.30
9 Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005 1.25
10 Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One 2012 1.18
11 Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 2011 1.15
12 Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res 2008 1.15
13 Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2008 1.15
14 Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003 1.12
15 Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett 2012 1.04
16 Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006 1.03
17 Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. Neurosurg Focus 2006 0.99
18 Interleukin-8 differentially regulates migration of tumor-associated and normal human brain endothelial cells. Cancer Res 2005 0.97
19 Characteristics of tumor-associated endothelial cells derived from glioblastoma multiforme. Neurosurg Focus 2006 0.97
20 Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005 0.95
21 Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb 2005 0.92
22 Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett 2011 0.91
23 Glioma-associated endothelial cells show evidence of replicative senescence. Exp Cell Res 2007 0.91
24 Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008 0.91
25 DNA methylation in the malignant transformation of meningiomas. PLoS One 2013 0.90
26 Functional and phenotypic differences between glioblastoma multiforme-derived and normal human brain endothelial cells. J Neurosurg 2005 0.89
27 A-Mode ultrasound guidance for pedicle screw advancement in ovine vertebral bodies. Spine J 2010 0.89
28 Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol 2009 0.89
29 Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Neurosurg Focus 2014 0.89
30 Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 2012 0.88
31 Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett 2012 0.87
32 Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. Neurosurg Focus 2006 0.87
33 Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus 2007 0.86
34 Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett 2009 0.85
35 A novel method for administering intrathecal chemotherapy in patients with leptomeningeal metastases and shunted hydrocephalus: case report. Neurosurgery 2010 0.85
36 Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Mol Cancer Ther 2010 0.84
37 Preclinical development of novel anti-glioma drugs targeting the endoplasmic reticulum stress response. Curr Pharm Des 2011 0.82
38 Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J Neurosurg 2005 0.82
39 Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. Neurosurg Focus 2006 0.82
40 An intensive, progressive exercise program reduces disability and improves functional performance in patients after single-level lumbar microdiskectomy. Phys Ther 2009 0.82
41 A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer 2011 0.81
42 Tamoxifen-induced growth arrest and apoptosis in pituitary tumor cells in vitro via a protein kinase C-independent pathway. Cancer Lett 2002 0.80
43 A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option. J Neurooncol 2014 0.80
44 Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology 2012 0.80
45 Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro. Cell Commun Adhes 2003 0.80
46 Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. J Neurosurg 2010 0.80
47 Genomic and transcriptome analysis revealing an oncogenic functional module in meningiomas. Neurosurg Focus 2013 0.80
48 Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 2015 0.79
49 Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurg Focus 2006 0.79
50 Potent mimicry of fibronectin-induced intracellular signaling in glioma cells by the homodimeric snake venom disintegrin contortrostatin. Neurosurgery 2005 0.79
51 MicroRNA-18a improves human cerebral arteriovenous malformation endothelial cell function. Stroke 2013 0.79
52 The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. J Neurosurg 2005 0.78
53 Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 2007 0.78
54 Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat. Vaccine 2008 0.78
55 Multiple signaling pathways are involved in endothelin-1-induced brain endothelial cell migration. Am J Physiol Cell Physiol 2006 0.77
56 Repositioning of Verrucosidin, a purported inhibitor of chaperone protein GRP78, as an inhibitor of mitochondrial electron transport chain complex I. PLoS One 2013 0.77
57 Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008 0.77
58 Lumbar facet joint and intervertebral disc loading during simulated pelvic obliquity. Spine J 2013 0.77
59 Surgical interventions for primary central nervous system lymphoma. Neurosurg Focus 2006 0.76
60 Transpedicular Corpectomy and Cage Placement in the Treatment of Traumatic Lumbar Burst Fractures. Clin Spine Surg 2017 0.75
61 DuraSeal Spinal Sealant as an Adjunct to Sutured Dural Repair in the Spine: Results of a Prospective, Multicenter, Randomized, Controlled Study: 928. Neurosurgery 2009 0.75
62 Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus 2015 0.75
63 Introduction: Glioblastoma: an update on pathophysiology and management strategies. Neurosurg Focus 2014 0.75